Early Detection of Breast Cancer and it Recurrence
Creators: name: University Of California Office Of The President
Publisher: name: University of California Office of the President
publisherIdentifier: https://ror.org/00dmfq477
publisherIdentifierScheme: ROR
Year: 2024

description: One of the most important aspects of the management of breast cancer is early identification of low- vs. high-risk patients with localized non-invasive breast ductal carcinoma in stiu (DCIS) for subsequently developing invasive breast cancer. Utilizing currently available prognostic markers, low- vs. high-risk patients with breast DCIS are difficult to be reliably identified prior to the development of invasive breast cancer which are often fatal.
 
 
 
 
 
 
 
 In addition, many patients with primary invasive breast cancer, with the exception of those with steroid hormone receptors positive or Her2/neu positive, are given adjuvant therapy without pre-screening for prognosis and effectiveness of therapy. Therefore, the current lack of an effective selection strategy, with the exceptions as stated above, means that many women are subjected to adjuvant therapy unnecessarily with side effects and significant costs.
 
 
 
 
 
 
 
 For these reasons, we have developed a potential prognostic biomarker (LEA.135), a cell surface marker with potential for pre-screening patients for an appropriate therapy. In a preliminary study funded by the CBCRP, LEA.135 expression has been shown to be independently and significantly associated with a decreased risk of developing recurrence (log rank p
 
 
 
 
 
 We wish to test the following hypotheses: 1) LEA.135expression can independently and significantly identify patients with breast DCIS at a decreased risk of developing invasive breast cancer; and 2) LEA.135 expression can identify a particular adjuvant therapy which is most effective in either LEA.135-positive or LEA.135-negative patients with primary invasive breast cancer. 
 
 
 
 
 
 
 
 To test the first hypothesis, LEA.135 expression will be determined using monoclonal anti-LEA.135 antibody by immuno-staining tissue sections from patients with breast DCIS (n=310). In order to perform multivariate analyses, the following information for each patient are available: age at diagnosis, follow-up after surgery (medium follow-up of 8 years), clinical outcome of the disease, tumor type, margin of the excised lesion and adjuvant therapy. To test the second hypothesis, LEA.135 expression will be determined in tissue sections from well-documented patients with primary invasive breast cancer (n=480). We will then evaluate the association of LEA.135 expression with three separate adjuvant therapies in terms of clinical outcome of the disease, measured as recurrence and overall survival of the patients with primary invasive breast cancer.
 
 
 
 
 
 
 
 What is innovative about this Innovative elements of the project is to establish LEA.135 expression as an independent and reliable marker for an early identification of low- vs. high-risk DCIS patients before the development of invasive breast cancer. Furthermore, the development of strategies, based on LEA.135 status, for pre-screening of patients with primary invasive breast cancer for choosing an effective adjuvant therapy would be an Movement over the current practice.